290 related articles for article (PubMed ID: 34310776)
1. Impact of hypoxia on the pathogenesis and therapy resistance in multiple myeloma.
Ikeda S; Tagawa H
Cancer Sci; 2021 Oct; 112(10):3995-4004. PubMed ID: 34310776
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-inducible microRNA-210 regulates the DIMT1-IRF4 oncogenic axis in multiple myeloma.
Ikeda S; Kitadate A; Abe F; Saitoh H; Michishita Y; Hatano Y; Kawabata Y; Kitabayashi A; Teshima K; Kume M; Takahashi N; Tagawa H
Cancer Sci; 2017 Apr; 108(4):641-652. PubMed ID: 28164410
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-inducible KDM3A addiction in multiple myeloma.
Ikeda S; Kitadate A; Abe F; Takahashi N; Tagawa H
Blood Adv; 2018 Feb; 2(4):323-334. PubMed ID: 29444873
[TBL] [Abstract][Full Text] [Related]
4. A DNA-binding Molecule Targeting the Adaptive Hypoxic Response in Multiple Myeloma Has Potent Antitumor Activity.
Mysore VS; Szablowski J; Dervan PB; Frost PJ
Mol Cancer Res; 2016 Mar; 14(3):253-66. PubMed ID: 26801054
[TBL] [Abstract][Full Text] [Related]
5. Dissecting the impact of bromodomain inhibitors on the Interferon Regulatory Factor 4-MYC oncogenic axis in multiple myeloma.
Agnarelli A; Mitchell S; Caalim G; Wood CD; Milton-Harris L; Chevassut T; West MJ; Mancini EJ
Hematol Oncol; 2022 Aug; 40(3):417-429. PubMed ID: 35544413
[TBL] [Abstract][Full Text] [Related]
6. Carrot and stick: HIF-alpha engages c-Myc in hypoxic adaptation.
Huang LE
Cell Death Differ; 2008 Apr; 15(4):672-7. PubMed ID: 18188166
[TBL] [Abstract][Full Text] [Related]
7. c-Myc is regulated by HIF-2α in chronic hypoxia and influences sensitivity to 5-FU in colon cancer.
Wang L; Xue M; Chung DC
Oncotarget; 2016 Nov; 7(48):78910-78917. PubMed ID: 27793037
[TBL] [Abstract][Full Text] [Related]
8. The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma.
Martin SK; Diamond P; Gronthos S; Peet DJ; Zannettino AC
Leukemia; 2011 Oct; 25(10):1533-42. PubMed ID: 21637285
[TBL] [Abstract][Full Text] [Related]
9. IRF4 addiction in multiple myeloma.
Shaffer AL; Emre NC; Lamy L; Ngo VN; Wright G; Xiao W; Powell J; Dave S; Yu X; Zhao H; Zeng Y; Chen B; Epstein J; Staudt LM
Nature; 2008 Jul; 454(7201):226-31. PubMed ID: 18568025
[TBL] [Abstract][Full Text] [Related]
10. A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways.
Podar K; Anderson KC
Cell Cycle; 2010 May; 9(9):1722-8. PubMed ID: 20404562
[TBL] [Abstract][Full Text] [Related]
11. C-terminal binding protein 2 is a novel tumor suppressor targeting the MYC-IRF4 axis in multiple myeloma.
Cheung CHY; Cheng CK; Leung KT; Zhang C; Ho CY; Luo X; Kam AYF; Xia T; Wan TSK; Pitts HA; Chan NPH; Cheung JS; Wong RSM; Zhang XB; Ng MHL
Blood Adv; 2024 May; 8(9):2217-2234. PubMed ID: 38457926
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation.
Long Y; Tsai WB; Chang JT; Estecio M; Wangpaichitr M; Savaraj N; Feun LG; Chen HH; Kuo MT
Oncotarget; 2016 Dec; 7(50):82658-82670. PubMed ID: 27765932
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells.
Kawano Y; Kikukawa Y; Fujiwara S; Wada N; Okuno Y; Mitsuya H; Hata H
Int J Oncol; 2013 Dec; 43(6):1809-16. PubMed ID: 24126540
[TBL] [Abstract][Full Text] [Related]
14. DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling.
Ishiguro K; Kitajima H; Niinuma T; Ishida T; Maruyama R; Ikeda H; Hayashi T; Sasaki H; Wakasugi H; Nishiyama K; Shindo T; Yamamoto E; Kai M; Sasaki Y; Tokino T; Nakase H; Suzuki H
Haematologica; 2019 Jan; 104(1):155-165. PubMed ID: 30171029
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells.
Mimeault M; Batra SK
J Cell Mol Med; 2013 Jan; 17(1):30-54. PubMed ID: 23301832
[TBL] [Abstract][Full Text] [Related]
16. NDRG3 lowers the metastatic potential in prostate cancer as a feedback controller of hypoxia-inducible factors.
Lee GY; Shin SH; Shin HW; Chun YS; Park JW
Exp Mol Med; 2018 May; 50(5):1-13. PubMed ID: 29760417
[TBL] [Abstract][Full Text] [Related]
17. IRF4 in multiple myeloma-Biology, disease and therapeutic target.
Agnarelli A; Chevassut T; Mancini EJ
Leuk Res; 2018 Sep; 72():52-58. PubMed ID: 30098518
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma.
Borsi E; Terragna C; Brioli A; Tacchetti P; Martello M; Cavo M
Transl Res; 2015 Jun; 165(6):641-50. PubMed ID: 25553605
[TBL] [Abstract][Full Text] [Related]
19. Inhibitor of differentiation 1 transcription factor promotes metabolic reprogramming in hepatocellular carcinoma cells.
Sharma BK; Kolhe R; Black SM; Keller JR; Mivechi NF; Satyanarayana A
FASEB J; 2016 Jan; 30(1):262-75. PubMed ID: 26330493
[TBL] [Abstract][Full Text] [Related]
20. HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
Ria R; Catacchio I; Berardi S; De Luisi A; Caivano A; Piccoli C; Ruggieri V; Frassanito MA; Ribatti D; Nico B; Annese T; Ruggieri S; Guarini A; Minoia C; Ditonno P; Angelucci E; Derudas D; Moschetta M; Dammacco F; Vacca A
Clin Cancer Res; 2014 Feb; 20(4):847-58. PubMed ID: 24297864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
